Top Companies in the Biopharmaceutical CDMO

The global biopharmaceutical contract manufacturing market is projected to reach 34.15 billion by 2030 from USD 22.40 billion in 2025, at a CAGR of 8.8% from 2025 to 2030. The growth of the biopharmaceutical contract manufacturing market can be attributed to industrial collaborations in drug discovery, strategic partnerships, and technological advancements in manufacturing.

The key players in the biopharmaceutical contract manufacturing industry with a strong global presence include Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Catalent, Inc. (US), Samsung Biologics (South Korea), Boehringer Ingelheim International GmbH (Germany), FUJIFILM Holdings Corporation (Japan), AbbVie, Inc. (US), Eurofins Scientific (Luxembourg), GenScript Biotech Corporation (US), AGC Inc. (Japan), Merck KGaA (Germany), JSR Corporation (Japan), IDT Biologika (Germany), Ajinomoto Bio-Pharma (Japan), Agilent Technologies, Inc. (US), and Asahi Kasei Corporation (Japan). These companies employ various growth strategies to enhance their international presence and strengthen their market positions. For instance, firms like WuXi Biologics and Lonza are expanding their manufacturing capabilities through investments in facilities and acquisitions and forming long-term collaborations with pharmaceutical companies to solidify their positions in clinical and commercial production.

To know about the assumptions considered for the study download the pdf brochure

Lonza (Switzerland)

Lonza (Switzerland) has solidified its position as a leading player in the biopharmaceutical contract manufacturing market. The company offers a comprehensive range of services, including the manufacturing of biologic drug substances and products and cGMP manufacturing for cell & gene therapies. Lonza's strong market presence is supported by a wide service portfolio, advanced production facilities, a broad global reach, and continuous investments to expand its manufacturing capabilities. In February 2023, Lonza upgraded its bioconjugation facility in Visp, Switzerland, increasing its capacity to support the development and production of preclinical, clinical, and commercial bioconjugates and antibody-drug conjugates. This enhancement further reinforces Lonza's market leadership and service offerings.

WuXi Biologics (China)

WuXi Biologics (China) is a leading player in the biopharmaceutical contract manufacturing market, providing a comprehensive range of services and maintaining a strong presence in developing countries. Its extensive expertise and service offerings have allowed the company to capture a significant market share and establish itself as a trusted partner in biopharmaceutical manufacturing. Additionally, the company focuses on inorganic growth strategies, such as acquisitions and collaborations, to enhance its capabilities and expand its global footprint. For example, in June 2025, WuXi Biologics announced the construction of a new microbial drug product (DP) manufacturing facility in the Wenjiang district of Chengdu, which will have a drug substance (DS) manufacturing capacity of 60,000 liters.

Market Ranking

The biopharmaceutical contract manufacturing market is highly consolidated, dominated by five major players: Lonza (Switzerland), WuXi Biologics (China), Thermo Fisher Scientific Inc. (US), AbbVie (US), and Samsung Biologics (South Korea). Together, they account for 50–55% of global revenues. These companies maintain their leadership through strategic investments, technological innovation, and global partnerships.

Lonza offers end-to-end services for biologics and complex therapies, focusing on quality and innovation. Thermo Fisher is recognized for its drug development and manufacturing services, supporting complex biologics projects. WuXi Biologics provides comprehensive services from discovery to commercial production, enabling efficient collaboration. Samsung Biologics specializes in developing and manufacturing therapeutic proteins and vaccines and is known for its strong technical expertise. AbbVie combines therapeutic knowledge with advanced manufacturing to produce reliable biologics.

The remaining 45–50% of the market is held by regional and emerging biotech companies, which are gaining traction through partnerships and technological advancements. The market is evolving with regulatory changes and increasing demand for personalized medicine, necessitating a focus on innovation and scalability.

Related Reports:

Biopharmaceutical CDMO Market by Service (Manufacturing, Fill-Finish), Type (Drug Substance, Drug Product), Scale (Clinical), Source (Mammalian), Therapy Area (Oncology), Molecule Type (mAbs, ADC, CGT, Vaccines) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com